Bio-Tissue, a subsidiary of TissueTech, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients.
“A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech Vice President of Sales, said in a company news release. “We are excited to be increasing our sales presence and are well positioned for continued growth. I’m thrilled to welcome our new hires to the organization and am confident this will better position us to continue to grow our user base.”
Bio-Tissue’s Prokera family of products are the only FDA-cleared amniotic membrane medical devices for the treatment of eye disease and injury, according to Bio-Tissue. Prokera, along with the company’s surgical products, AmnioGraft and AmnioGuard, contain the only cryopreserved amniotic membrane that has been recognized by the FDA for its anti-scarring, anti-inflammation, and anti-angiogenesis properties.
Bio-Tissue is a wholly owned subsidiary of TissueTech, which recently closed on an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners.
“This funding not only helps us support ongoing investments in our commercial activities such as this, but also helps drive the clinical research, manufacturing and product development activities needed to support our transformation to a biologics therapy provider,” TissueTech co-founder and Chief Executive Officer Amy Tseng said in a news release. “We’re excited to announce the expansion and to carry the great momentum we are building into an amazing year of growth and development in 2020.”